Device Trial Radar · NCT04320823
IMPACT (Improving Plasma Collection) Clinical Trial
Last checked: Nov 19, 2026Latest source record: Apr 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,443
Actual
Start
Jan 6, 2020
Primary completion
Mar 27, 2020
Study completion Apr 27, 2020
Sponsor
- Lead sponsor
- Haemonetics CorporationPublic (HAE)
- Sponsor type
- Industry
- First posted
- Mar 25, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 66 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Prospective, multi-center, randomized, controlled clinical trial to study the safety and effectiveness of a novel plasma collection system software.
Conditions
- Apheresis Related Hypotension
Interventions
Updated Plasma Collection FeatureDevice
Plasma collection using a novel, patented system that supports a more individualized collection approach.
Current Plasma Collection ApproachDevice
Plasma collection using the current collection approach.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Significant Hypotensive Adverse EventsTime frame: Up to approximately 3 months (total trial duration during which donors could donate), depending on time of enrollment into the trial.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Octapharma Plasma
Wichita, Kansas
Octapharma Plasma
Charlotte, North Carolina
Octapharma Plasma
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.